Certara
Biotechnology, Consulting, Pharmaceutical · 1,403 employees
Certara accelerates medicines using proprietary biosimulation software, technology, and services to transform traditional drug discovery and development. Its clients include more than 2,000 biopharmaceutical companies, academic institutions, and regulatory agencies across 62 countries.
Funding history
- Funding Round — $8.6M — Apr 2026
- Funding Round — $5.7M — Mar 2025
- Funding Round — Undisclosed — Sep 2021
Recent signals
- Apr 28, 2026: Raised $8.6M
- Dec 11, 2025: Certara Appoints Jon Resnick as Chief Executive Officer
- Nov 03, 2025: Launched Certara has launched Certara IQ, an AI-powered QSP modeling platform aimed at enhancing drug discovery processes.
- Oct 16, 2025: SEC 8-K (1.01): On October 16, 2025, Certara USA, Inc., an indirect subsidiary of Certara, Inc., along with its affiliates, entered into a Sixth Amendment to an existing Credit Agreement originally dated August 15, 2017. This amendment involves multiple parties, including Certara Holdings and various lenders, specifically Bank of America, N.A., acting as the administrative agent. The amendment updates terms of the financing arrangement with the lenders, though specific financial amounts or strategic implications were not disclosed in this excerpt. The action reflects ongoing adjustments to their financial structure and potentially aims to enhance liquidity or revise financial covenants in response to industry conditions.
- Jul 31, 2025: Certara Appoints Christopher Bouton as Chief Technology Officer
- Jul 08, 2025: Certara Expands Partnership with Merck to Enhance Drug Development Data Standards
- Apr 01, 2025: Launched Certara, Inc. has launched the latest version of the Simcyp™ Simulator to enhance drug development and regulatory decision-making.
- Mar 28, 2025: Raised $5.7M
See plans & pricing → Track Certara’s funding, hiring, and signals — with verified contacts — on Fundz.